The ESCMID Study Group for Bloodstream Infections, Endocarditis, and Sepsis (ESGBIES) is committed to improving the management of bloodstream infections, infective endocarditis, and sepsis. This network of dedicated experts focuses on:
Through a strong dedication to research, ESGBIES drives forward to create educational initiatives, such as in-person seminars, courses, and webinars, as well as joint projects. Both longstanding and new members are appreciated for playing an invaluable role in this shared mission.
ESGBIES is happy to announce two ESGBIES AWARDS for 2025-2026:
Best Article Award
The ESGBIES Best Article Award aims to recognize outstanding collaborative research in Clinical Microbiology (CM) and Infectious Diseases (ID), co-authored by researchers from different countries. The award includes a monetary prize of 1,000 euros.
Application open: September 1st and September 15th, 2025
Best Abstract Award
The ESGBIES Best Abstract Award recognizes ESCMID Young Scientist Members who present their research at ESCMID Global. The award includes:
• 500 euros for the 2 best abstracts
Application open: 15 January to 12 February 2026
Interested?
Apply here (Study Group Travel Grant):
Find out more about the eligibility criteria below
Blood culture practices and microbiological capacity for sepsis diagnostics in Europe (2021-2022): a cross-sectional analysis of the European Sepsis Care Survey.
Scheer CS, Giamarellos-Bourboulis EJ, Annane D, Artigas A, Aslan AT, Bottari G, Bouma HR, Černý V, Curić Radivojević R, Dewitte K, Filipescu D, Gründling M, Hästbacka J, Laribi S, Lassen A, Lebedinskii K, Linder A, Máca J, Malbrain MLNG, Monti G, Ostermann M, Osthoff M, Paiva JA, Sabbatucci M, Śmiechowicz J, Ştefan MG, Vollmer M, Vuković N, Zaragkoulias K, Reinhart K, Ferrer R, Idelevich EA; European Sepsis Care Study Group on behalf of the ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES) and the European Sepsis Alliance (ESA). Lancet Reg Health Eur. 2025 Dec 18;62:101570
What is the impact of anti-enterococcal empirical therapy on survival of patients with enterococcal bloodstream infections?
Bussini L, Bavaro DF, Brunetta E, Carella F, Accornero S, Rosselli Del Turco E, Pasquini Z, Scolz K, Tedeschi S, Pascale R, Ambretti S, Banchini I, Pericàs JM, Hernández P, Carvalho-Brugger S, Mondatore D, Casana M, Cento V, Giannella M, Viale P, Bartoletti M. Clin Infect Dis. 2025 Jun 18:ciaf323
Does Biological Sex Determine the Natural History and Management of Infective Endocarditis?
Grillo S, Isler B, Bonet-Basiero A, Roselló-Díez E, Escolà-Vergé L; Study Group for Bloodstream Infections, Endocarditis, and Sepsis (ESGBIES). Can J Cardiol. 2025 Nov 4:S0828-282X(25)01300-5
Early oral switch therapy for infective endocarditis: An international cross-sectional survey on current use in clinical practice
Mathé, P.; Hornuss, D.; Giesen, R.; Camp, J.; Isler, B.; Bartoletti, M.; Lamy, B.; Escolà-Vergé, L.; Miró Meda, J. M.; Rieg, S. on behalf of ESGBIES. CMI Communications 2025, 2 (1), 105063
How to manage patients receiving long-term suppressive antibiotic treatment for infective endocarditis: the role of [18F]-FDG-PET/CT imaging - An international multidisciplinary survey.
Pascale R, Fernández-Hidalgo N, Tazza B, Bartoletti M, Bertolino L, Durante-Mangoni E, Pérez AR, Pizzi MN, Viale P, Giannella M; European Society of Clinical Microbiology and Infectious Diseases Study Group on Implant Associated Infections (ESGIAI); European Society of Clinical Microbiology and Infectious Diseases Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES). J Nucl Cardiol. 2025 Sep 27:102505
An Update on Recent Clinical Trial Data in Bloodstream Infection.
Stewart AG, Simos P, Sivabalan P, Escolà-Vergé L, Garnham K, Isler B; ESGBIES Study Group. Antibiotics (Basel). 2024 Nov 1;13(11):1035
Risk factors for Gram-negative bacterial infection of cardiovascular implantable electronic devices: multicentre observational study (CarDINe Study).
Pascale R, Toschi A, Aslan AT, Massaro G, Maccaro A, Fabbricatore D, Dell'Aquila A, Ripa M, Işık ME,Kızmaz YU, Iacopino S, Camici M, Perna F, Akinosoglou K, Karruli A, Papadimitriou-Olivgeris M, Kayaaslan B, Bilir YA, Evren Özcan E, Turan OE, Işık MC, Pérez- RodríguezMT, Yagüe BL, Quirós AM, Yılmaz M, Petersdorf S, De Potter T, Durante- Mangoni E, Akova M, Curnis A,Gibertoni D, Diemberger I, Scudeller L, Viale P, Giannella M, CarDINe Study Group. Int J Antimicrob Agents. 2023;61(3):106734.
If you have questions or comments for our study group, we warmly invite you to contact us!